Jefferies analysts
Biogen, Stoke Boost Epilepsy Drug’s Blockbuster Potential With Early Seizure Reduction Data
Biogen; Stoke Therapeutics; zorevunersen; Dravet syndrome; epilepsy; antisense oligonucleotide; seizure reduction; blockbuster drug; EMPEROR Phase III trial; American Epilepsy Society 2025; Jefferies analysts; natural history controls; SCN1A